Marksans Pharma Ltd vs Supriya Lifescience Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Marksans Pharma Ltd is ₹ 196.35 as of 06 May 15:30 . The P/E Ratio of Marksans Pharma Ltd changed from 8.7 on March 2021 to 26.5 on March 2025 . This represents a CAGR of 24.95% over 5 yearsThe P/E Ratio of Supriya Lifescience Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Marksans Pharma Ltd changed from ₹ 2044 crore on March 2021 to ₹ 10076 crore on March 2025 . This represents a CAGR of 37.58% over 5 yearsThe Market Cap of Supriya Lifescience Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Marksans Pharma Ltd for the Dec '25 is ₹ 774.57 crore as compare to the Sep '25 revenue of ₹ 741.98 crore. This represent the growth of 4.39% The revenue of Supriya Lifescience Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Marksans Pharma Ltd for the Dec '25 is ₹ 180.89 crore as compare to the Sep '25 ebitda of ₹ 166.07 crore. This represent the growth of 8.92% The ebitda of Supriya Lifescience Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Marksans Pharma Ltd changed from ₹ 89.07 crore to ₹ 113.69 crore over 7 quarters. This represents a CAGR of 14.97% The net profit of Supriya Lifescience Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Marksans Pharma Ltd changed from 10.4 % on March 2021 to 19.26 % on March 2025 . This represents a CAGR of 13.12% over 5 yearsThe Dividend Payout of Supriya Lifescience Ltd changed from 3.2 % on March 2021 to 4.28 % on March 2025 . This represents a CAGR of 5.99% over 5 years .

About Marksans Pharma Ltd

Marksans Pharma Limited was formerly incorporated as 'Tasc Pharmaceuticals Limited' in April, 1982.
Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited from 10th October, 2005.
The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
Marksans Pharma Limited (formerly M/s.

About Supriya Lifescience Ltd

Supriya Lifescience Limited was initially constituted on October 29, 1985, as a 'Partnership Firm under the name M/s Supriya Chemicals'.
The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007.
Upon the conversion of M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai. The Company commenced operations in April, 2008.
It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs).
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development.

FAQs for the comparison of Marksans Pharma Ltd and Supriya Lifescience Ltd

Which company has a larger market capitalization, Marksans Pharma Ltd or Supriya Lifescience Ltd?

Market cap of Marksans Pharma Ltd is 8,897 Cr while Market cap of Supriya Lifescience Ltd is 5,661 Cr

What are the key factors driving the stock performance of Marksans Pharma Ltd and Supriya Lifescience Ltd?

The stock performance of Marksans Pharma Ltd and Supriya Lifescience Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Marksans Pharma Ltd and Supriya Lifescience Ltd?

As of May 6, 2026, the Marksans Pharma Ltd stock price is INR ₹196.35. On the other hand, Supriya Lifescience Ltd stock price is INR ₹703.45.

How do dividend payouts of Marksans Pharma Ltd and Supriya Lifescience Ltd compare?

To compare the dividend payouts of Marksans Pharma Ltd and Supriya Lifescience Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.